Most Read Articles
Stephen Padilla, 09 Nov 2020
Tocilizumab (TCZ) therapy appears to be effective in patients at risk of cytokine release syndrome (CRS) from the novel coronavirus disease (COVID-19), suggests a study presented at ID Week 2020. Those receiving TCZ in a nonintensive care unit (non-ICU) setting show better response than ICU patients.
Stephen Padilla, 10 Nov 2020
Patients with chronic obstructive pulmonary disease (COPD) seem to benefit from using chlorhexidine oral rinses twice daily as shown by the reduction in oral and sputum microbiota alpha diversity and by clinically significant improvements in COPD symptoms, according to a study presented at ID Week 2020.
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.

Canagliflozin reduces NT-proBNP concentrations

06 Nov 2020

Use of canagliflozin leads to a decrease in amino-terminal pro–B-type natriuretic peptide (NT-proBNP) concentrations as compared with placebo, but the reduction in NT-proBNP explains only a small part of the benefit of this agent on heart failure (HF) events, suggests a recent study.

The investigators sought to determine the associations between baseline NT-proBNP and cardiovascular, renal, and mortality outcomes, as well as intervention-related changes among participants of the Canagliflozin Cardiovascular Assessment Study (CANVAS).

A total of 4,330 participants were included in CANVAS, of whom 3,587 had their NT-proBNP measured at baseline, 2,918 at 1 year, and 995 at 6 years. The median baseline NT-proBNP concentration was 91 pg/ml; 39.3 percent had NT-proBNP ≥125 pg/ml.

Participants with investigator-reported HF (13 percent) had higher NT-proBNP than those without (187 vs 81 pg/ml), with substantial overlap between groups. By 1 year, NT-proBNP increased with placebo but decreased with canagliflozin by 11 percent (geometric mean ratio, 0.89, 95 percent confidence interval [CI], 0.84–0.94; p<0.001). At 6 years, NT-proBNP was lower with canagliflozin (p=0.004).

Baseline NT-proBNP ≥125 pg/ml was prognostic for incident hospitalization for HF (HHF; hazard ratio [HR], 5.40, 95 percent CI, 2.67–10.9), HHF/cardiovascular death (HR, 3.52, 95 percent CI, 2.38–5.20), and all-cause mortality (HR, 2.53, 95 percent CI, 1.78–3.61) in adjusted models. In mediation analyses, 10.4 percent of the effects of canagliflozin on HHF were attributed to NT-proBNP reduction.

“Canagliflozin reduces cardiovascular events including hospitalization for HF in patients with type 2 diabetes and cardiovascular risk,” the investigators said. “Elevated NT-proBNP concentrations are associated with HF diagnosis and predict cardiovascular risk.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 09 Nov 2020
Tocilizumab (TCZ) therapy appears to be effective in patients at risk of cytokine release syndrome (CRS) from the novel coronavirus disease (COVID-19), suggests a study presented at ID Week 2020. Those receiving TCZ in a nonintensive care unit (non-ICU) setting show better response than ICU patients.
Stephen Padilla, 10 Nov 2020
Patients with chronic obstructive pulmonary disease (COPD) seem to benefit from using chlorhexidine oral rinses twice daily as shown by the reduction in oral and sputum microbiota alpha diversity and by clinically significant improvements in COPD symptoms, according to a study presented at ID Week 2020.
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.